MND Scotland welcomes the publication of the MIROCALS trial in The Lancet today. We have been campaigning alongside the MND Association and My Name’5 Doddie Foundation for the publication of this important trial and are now keen to ensure we understand the implications of the data so we can provide the right information to patients and their families. 

MIROCALS was a pan-European clinical trial that investigated the impact of low dose interleukin 2 (IL-2) in people with MND. It announced encouraging preliminary results in December 2022, and publication of the data has been greatly anticipated by the MND community. 

This data has now been peer reviewed and was published in the scientific journal, The Lancet on 9 May 2025. You can access the article here. 

The charities are working with the UK MND Clinical Studies Group – which includes leading neurologists, researchers and people with MND. We have asked this group to provide further guidance on whether the data indicates a positive benefit of low dose IL-2 for people with MND, as soon as possible. We expect this to occur in the coming weeks and, once this happens, we will agree next steps. 

The three main UK MND charities are committed to working collaboratively to pursue every avenue available to us to make proven treatments available to people with MND as quickly as possible and on an equitable basis.